Drug Topics

SEPTEMBER 22, 2024

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Vaccines 176

Vaccines 176

Med Ed 101

SEPTEMBER 22, 2024

Fluctuations in blood sugars can be very distressing for patients. This is especially true in patients who have adequate control of their diabetes. Adverse effects can lead to an escalation of diabetes medication. I’ll share my top 5 drugs that cause hyperglycemia and ultimately contribute to the prescribing cascade. Corticosteroids The first medication I have […] The post Top 5 Drugs That Cause Hyperglycemia appeared first on Med Ed 101.

80

80

Pharmacy Times

SEPTEMBER 22, 2024

The researchers estimate that pregnancy losses because of malaria and parasitemia risk before conception was reduced by 65% to 86%.

Vaccines 112

Vaccines 112

pharmaphorum

SEPTEMBER 22, 2024

FTC lawsuit accuses top three PBMs of using a perverse drug rebate system to artificially inflate the price of insulin products and their profits

69

69

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The FDA Law Blog

SEPTEMBER 22, 2024

By Steven J. Gonzalez & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — On August 22, 2024, FDA hosted a webinar to provide further guidance on the regulatory requirements it intends to apply to Laboratory Developed Test (LDT) developers in Stage 1 of the phaseout policy of the LDT Final Rule – during which FDA has said laboratories developing LDTs will need to comply with Medical Device Reporting (MDR) (21 CFR Part 803), Corrections and Removals (21 CFR Part 806), and Complaint

FDA 64

FDA Labelling Communication 64